[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521246":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":42,"responsibleParty":58,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":11,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Indacaterol + mometasonefluroate","EXPERIMENTAL",null,[13,14],"Drug: Indacaterol and Mometasonefluroate (low dose)","Drug: Indacaterol and Mometasonefluroate (high dose)",{"label":16,"type":17,"description":11,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR",[19],"Drug: Placebo",[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Indacaterol and Mometasonefluroate (low dose)","Participants are administered 125 µg indacaterol + mometasonefluroate",[9],{"type":22,"name":16,"description":27,"armGroupLabels":28,"otherNames":11},"Participants are administered placebo",[16],{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"Indacaterol and Mometasonefluroate (high dose)","Participants are administered 500 µg indacaterol + mometasonefluroate",[9],[34],{"name":35,"affiliation":5,"role":36},"Morten Hostrup, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":11,"email":41},"CONTACT","+4535321595","mhostrup@nexs.ku.dk",[43],{"facility":44,"status":45,"city":46,"state":11,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"August Krogh Building","RECRUITING","Copenhagen","2100","Denmark","DK",{"type":51,"coordinates":52},"Point",[53,54],12.56553,55.67594,{"lat":54,"lon":53},[57],{"name":35,"role":39,"phone":11,"phoneExt":11,"email":11},{"type":59,"investigatorFullName":35,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Associate Professor","100521246","u-labaics-effects-on-exercise-performance-indacaterol-100521246",false,"NCT06067100","U-LABA\u002FICS Effects on Exercise Performance, Indacaterol","Physiological Response to U-LABA\u002FICS With Emphasis on Exercise Performance, Indacaterol","Inclusion Criteria:\n\n* Age 18-39\n* Physically active \\> 5 h weekly\n* Maximal oxygen consumption classified as high or very high\n\nExclusion Criteria:\n\n* Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist\u002Fcorticosteroid\n* ECG abnormality\n* ACQ score \\> 1.5\n* Severe bronchial hyperreactivity as determined by mannitol test\n* FEV1\u002FFVC ratio \\\u003C 0.7 determined with spirometry\n* Chronic illness determined to be a potential risk for participant during study\n* In chronic treatment with medication that may interfere with study results\n* Pregnancy\n* Smoker\n* Blood donation during the past 3 months",true,"ALL","18 Years","39 Years",{"count":73,"type":74},30,"ESTIMATED","INTERVENTIONAL",[77],"NA","The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate",[80],"Exercise Performance","2025-04-07",{"date":83,"type":84},"2025-04-09","ACTUAL",{"date":86,"type":84},"2024-01-15",{"date":88,"type":74},"2026-12-01",{"name":35,"class":6},1]